The RapidPoint 500e blood gas analyzer from Siemens Healthineers, Erlangen, Germany, has received FDA clearance. The analyzer generates blood gas, cooximetry, electrolyte, metabolite, and neonatal bilirubin results, which are used to diagnose and monitor critically ill patients in the intensive care unit, operating room, or emergency room. Already available in countries requiring the CE mark, the RapidPoint 500e blood gas analyzer is now available for critical care testing in the United States.
“Point-of-care teams monitoring respiratory conditions in critical care settings need a blood gas testing solution that delivers fast, accurate results and increases workflow efficiencies. A safe operating environment amid growing concerns about cybersecurity threats in healthcare is also important,” says Christoph Pedain, PhD, head of point-of-care diagnostics for Siemens Healthineers. “The RapidPoint 500e blood gas analyzer has become a trusted instrument in Europe’s endeavor to combat covid-19 and to help address an unprecedented demand for blood gas testing in affected respiratory patients.”
The RapidPoint 500e blood gas analyzer is an essential instrument supporting covid-19 response efforts, where blood gas testing plays a critical role in managing infected patients and monitoring their respiratory distress. Routine blood gas testing is also performed when patients require mechanical ventilation. Arterial blood gas tests provide the status of a patient’s oxygenation levels and enable healthcare providers to determine whether adjustments to ventilator settings or other treatments are required.
For mor information, visit Siemens Healthineers.